CASC19: A Potential Drug Target and Biomarker for Cancer (G103021165)

Target Name: CASC19

NCBI ID: G103021165

CASC19

Other Name(s): cancer susceptibility 19 | Cancer susceptibility 19 | LINC01245 | CARLo-6 | CARLO6

CASC19: A Potential Drug Target and Biomarker for Cancer

Cancer Susceptibility 19 (CASC19) is a protein that is expressed in a variety of tissues and cells in the human body. It is also known as GSDM2 (Growth arrest and DNA damage-inducible gene 2) and has been shown to play a role in the development and progression of various cancers.

One of the most promising aspects of CASC19 is its potential as a drug target.CASC19 has been shown to be involved in a variety of cellular processes that are relevant to cancer development, including cell growth, apoptosis (programmed cell death), and inflammation. It has also been shown to be involved in the development of cancer-initiating events, such as the formation of tumors.

In addition to its potential as a drug target, CASC19 has also been shown to be a potential biomarker for cancer. By measuring the level of CASC19 in cancer cells, researchers may be able to monitor the effectiveness of different treatments and identify new biomarkers for cancer.

CASC19 is a transmembrane protein that is expressed in a variety of tissues and cells in the human body. It is made up of four domains: an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for interacting with other proteins and molecules outside of the cell, the transmembrane domain is responsible for the protein's ability to travel through the cell membrane, and the intracellular domain is responsible for interacting with inside the cell.

CASC19 is involved in a variety of cellular processes that are relevant to cancer development. For example, it has been shown to be involved in cell growth, apoptosis, and inflammation.CASC19 has also been shown to be involved in the development of cancer-initiating events, such as the formation of tumors.

One of the most promising aspects of CASC19 is its potential as a drug target.CASC19 has been shown to be involved in a variety of cellular processes that are relevant to cancer development, including cell growth, apoptosis, and inflammation. It has also been shown to be involved in the development of cancer-initiating events, such as the formation of tumors.

In addition to its potential as a drug target, CASC19 has also been shown to be a potential biomarker for cancer. By measuring the level of CASC19 in cancer cells, researchers may be able to monitor the effectiveness of different treatments and identify new biomarkers for cancer.

In conclusion, CASC19 is a protein that is expressed in a variety of tissues and cells in the human body. It is involved in a variety of cellular processes that are relevant to cancer development, including cell growth, apoptosis, and inflammation. Additionally, CASC19 has been shown to be involved in the development of cancer-initiating events and may be a potential drug target and biomarker for cancer. Further research is needed to fully understand the role of CASC19 in cancer development and treatment.

Protein Name: Cancer Susceptibility 19

The "CASC19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CASC19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets